Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Medicines & Healthy Lifestyle

Lomecel-B Granted Fast Track Status for Hypoplastic Left Heart Syndrome

admin by admin
September 1, 2022
in Medicines & Healthy Lifestyle


The Food and Drug Administration (FDA) has granted Fast Track designation to Lomecel-B™, an investigational allogeneic, bone marrow-derived medicinal signaling cell product for treatment of hypoplastic left heart syndrome (HLHS) in infants.

Lomecel-B is derived from culture-expanded medicinal signaling cells that are sourced from the bone marrow of young, healthy adult donors, and is delivered via intramyocardial injection. In the phase 1 ELPIS trial (ClinicalTrials.gov Identifier: NCT03525418), Lomecel-B was well tolerated with no major adverse cardiac events 1-year post-surgery, and/or treatment-related infections. 

The Company is currently evaluating the efficacy and safety of Lomecel-B in infants with HLHS who are undergoing Stage II reconstructive cardiac surgery in the ongoing phase 2a ELPIS II trial (ClinicalTrials.gov Identifier: NCT04925024).


Continue Reading

The FDA previously granted Orphan Drug and Rare Pediatric Disease designations to Lomecel-B for HLHS.

“Fast Track Designation represents a significant milestone in our efforts to develop Lomecel-B™ as a treatment for infants with HLHS,” said Chris Min, MD, PhD, Longeveron’s Interim Chief Executive Officer and Chief Medical Officer. “Fast Track Designation underscores the urgent need in HLHS, and we look forward to continuing to work closely with the FDA to bring this potential new therapy to infants as expeditiously as possible.”

Reference

US Food and Drug Administration (FDA) grants Fast Track designation for Longeveron’s Lomecel-B™ product for treatment of hypoplastic left heart syndrome (HLHS) in infants. News release. Longeveron Inc. Accessed August 31, 2022. https://www.globenewswire.com/news-release/2022/08/31/2507637/0/en/U-S-Food-and-Drug-Administration-FDA-Grants-Fast-Track-Designation-for-Longeveron-s-Lomecel-B-Product-for-Treatment-of-Hypoplastic-Left-Heart-Syndrome-HLHS-in-Infants.html

This article originally appeared on MPR

Topics:

Cardiovascular Disease
Pediatrics



Source link

Previous Post

People With This Blood Type May Have Higher Risk Of Early Stroke: Study

Next Post

Health Bulletin 1/September/2022

Next Post

Health Bulletin 1/September/2022

Recommended

Fake Positive Reviews; Low Quality Guidelines; and CDC Reorg

August 18, 2022

Vitamin B1 Is Vital to Protect Against Infectious Disease

January 31, 2023

Don't miss it

Pharmaceutical

Mr. President, health care has a data problem

February 8, 2023
Medicines & Healthy Lifestyle

Amazon’s Virtual Health Clinic Raises Patient Privacy Issues

February 8, 2023
Medicines & Healthy Lifestyle

Know The Health Benefits Of Irish Sea Moss

February 8, 2023
News

Sharp Cutoff at Age 70

February 8, 2023
Pharmaceutical

Medical Bulletin 8/February/2023

February 8, 2023
Pharmaceutical

Biden to call for expanding caps on insulin prices

February 7, 2023

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.